In this file
Comparing alternatives to Direct Meds is easier when you first identify what needs to change. DirectMeds describes both sublingual and injectable options. The clinical comparison needs the exact route and formulation before a bulk discount or a lower starting amount can be evaluated sensibly.
The provider’s current comparison point is: A sublingual preparation is a separate product from an injection or an approved tablet. The entries below offer different care and payment arrangements to examine against that point.
How to use this shortlist
CoreAge Rx is listed first under a commercial partnership. The first position is predetermined by that relationship, and links may earn compensation. It is not an independent finding that CoreAge has the safest medicine, the lowest total price, or the strongest patient outcomes.
Use Direct Meds’s documented arrangement as the baseline, then test the alternatives against route-specific evidence and bulk-plan terms. We compare public care descriptions and payment terms. We have not purchased treatment, audited every professional license, or timed the support response. Use the linked source notes and obtain a current personal quote.
01. CoreAge Rx · sponsored first position
This is the paid featured reference for the question in this guide. Its placement does not establish that every feature discussed here is available through its program. Ask about the exact product and care access before assuming a match.
CoreAge Rx provides an online route to medical assessment and, where a clinician prescribes, pharmacy fulfillment. The service is our paid featured partner. That commercial relationship buys its prominent position here; it does not establish a better medicine, a better outcome, or suitability for any particular reader.
The sale offer shows starting equivalents of $99 for semaglutide and $149 for tirzepatide, without a separate membership charge. Its billing explanation uses a three-month example: $149 per month becomes a single $447 payment. A reader should obtain the duration and total for the selected prescription rather than assuming that the smaller figure is charged monthly.
A question to put to the provider: Can you send the full payment schedule and the name of my dispensing pharmacy before I accept the offer?
Read the CoreAge Rx provider file and cost explanation for the connected details.
02. Strut Health
The comparison point for Strut Health: The buccal lozenge and injectable semaglutide are different formulations.
Strut describes an online questionnaire, physician review, and automatic refills. Its lozenge contains vitamin B6 and is used inside the cheek; it should not be confused with a branded semaglutide tablet.
The page lists $129 for a monthly injectable vial and $199 for a thirty-day lozenge supply, with consultations and shipping included and final price determined after assessment. Compare the exact product and route, not just the ingredient name.
A question to put to the provider: What supports this specific formulation, and when must I act to stop the next automatic refill?
The Strut Health alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
03. Rex MD
The comparison point for Rex MD: The current offer names branded Wegovy tablets rather than a generic oral category.
Rex MD’s weight-management page describes online assessment and a branded Wegovy tablet pathway involving NovoCare. The product is distinct from a compounded lozenge or a sublingual preparation.
The page advertises medication and provider care starting at $349 monthly and describes its listed titration strengths as covered by the offer. Confirm the exact branded product, eligibility, and later recurring amount.
A question to put to the provider: Does the written quote cover this branded tablet and continuing clinical care at the prescribed strength?
The Rex MD alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
04. Henry Meds
The comparison point for Henry Meds: The treatment route and remaining commitment affect the meaning of the starting price.
Henry Meds describes an intake followed by a healthcare-provider assessment and a prescription shipment when appropriate. The service presents visits, medication, and supplies as a bundle, while offering more than one route and program duration.
Its weight-management FAQ advertises GLP-1 care beginning at $179 per month. That figure depends on the selected plan and prescription. A compounded oral preparation and an injection should have separate quotes and separate clinical discussions; one low starting figure cannot describe them both reliably.
A question to put to the provider: What remains payable if I stop this specific plan, and which clinical services continue during the paid term?
Read the Henry Meds provider file and cost explanation for the connected details.
05. Hello Alpha
The comparison point for Hello Alpha: Appointment-free care and pharmacy coverage are separate parts of the decision.
Hello Alpha describes a dedicated provider through appointment-free online visits and says it prescribes FDA-approved medicines. Its list includes products with different indications, which require individual clinical assessment.
Alpha Plus+ weight-care membership is advertised at $79 monthly. Prescription costs remain dependent on the product, pharmacy, and insurance. The care fee does not guarantee a prescription, covered drug, or refund after an authorization denial.
A question to put to the provider: Which medicine and indication would the clinician consider, and what would the pharmacy charge in addition to membership?
The Hello Alpha alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
06. Fifty 410
The comparison point for Fifty 410: Different package tiers mean a starter total is not the whole price story.
Fifty 410 describes online provider assessment and portal-based follow-up. The pricing material separates semaglutide purchased monthly from three-month tirzepatide packages and includes clinical review, medicine, and shipment in the listed packages.
The tirzepatide starter total is $399 for three months, with other listed tiers at $499 and $549. A monthly semaglutide option is $199. Match the quoted tier and treatment duration to the prescription before comparing those amounts.
A question to put to the provider: Does this package suit an existing patient, and what would the following package cost?
The Fifty 410 alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
Your starting point: Direct Meds
DirectMeds describes clinical care and follow-ups bundled with medication. Its page distinguishes a monthly arrangement from bulk purchases and discusses both sublingual and injectable treatment.
Displayed starting amounts are $249 for sublingual semaglutide and $297 for injections, with six- and twelve-month bulk options and introductory offers also described. A route change should not be evaluated only as a price reduction.
What evidence concerns this exact formulation, and what is the complete payment if I select a bulk term?
Make the decision concrete
Bring these three checks to the shortlist. If an answer describes another product, a different payment period, or a service you are not eligible for, the comparison is not finished.
- Obtain new product-specific instructions when changing route; do not translate an injection amount into an oral amount.
- Request the named product, total initial payment, and next renewal in the same written quote.
- Confirm how the receiving clinician reviews existing treatment and how questions are handled between orders.
Separate the product from the provider
FDA approval belongs to a particular drug product, not to a review site’s list or a telehealth brand. A compounded preparation has not received that approval. Ingredient similarity does not establish the same route, formulation, manufacturing controls, or evidence.
Ask the clinician why the exact prescription fits your medical needs. Then ask the pharmacy for the label and instructions appropriate to that product. Read what compounding and FDA approval mean if those terms are being used interchangeably in a promotion.
Before accepting another offer
Keep the current agreement, prescription label, and any pending order information together. A new enrollment does not automatically stop the previous company’s next charge or authorize a continuation prescription.
Use the questions-before-purchase checklist to record the answers in your own words. A useful next step is a clear conversation and a complete proposal, not a decision based on a rank alone.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- CoreAge Rx: official treatment overview ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: current sale offer ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: plan billing explained ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: contact and professional-entity disclosures ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: purchasing process ↗Provider-published information · Checked September 22, 2026
- Strut Health: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- FDA: Wegovy semaglutide tablets, NDA 218316 approval letter ↗Regulatory source · Checked September 22, 2026
- Rex MD: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- GLP-1 Weight Loss Treatment | Henry ↗Provider-published information · Checked September 22, 2026
- Hello Alpha: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- Fifty 410: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- Direct Meds: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026